US Bancorp DE Has $228,000 Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)

US Bancorp DE raised its position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) by 12,452.9% during the third quarter, according to its most recent filing with the SEC. The firm owned 8,536 shares of the company’s stock after purchasing an additional 8,468 shares during the period. US Bancorp DE’s holdings in Edgewise Therapeutics were worth $228,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Quest Partners LLC raised its stake in Edgewise Therapeutics by 156.9% during the second quarter. Quest Partners LLC now owns 1,742 shares of the company’s stock worth $31,000 after buying an additional 1,064 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in Edgewise Therapeutics during the 2nd quarter worth about $35,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Edgewise Therapeutics by 21.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,392 shares of the company’s stock worth $88,000 after acquiring an additional 604 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of Edgewise Therapeutics by 37.3% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,751 shares of the company’s stock valued at $105,000 after purchasing an additional 1,561 shares during the period. Finally, Arizona State Retirement System bought a new stake in shares of Edgewise Therapeutics during the 2nd quarter valued at about $188,000.

Insiders Place Their Bets

In other Edgewise Therapeutics news, CFO R Michael Carruthers sold 125,092 shares of the firm’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $28.57, for a total transaction of $3,573,878.44. Following the transaction, the chief financial officer now directly owns 6,904 shares in the company, valued at approximately $197,247.28. This trade represents a 94.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Joanne M. Donovan sold 7,162 shares of the company’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $28.29, for a total transaction of $202,612.98. Following the completion of the sale, the chief marketing officer now owns 14,538 shares of the company’s stock, valued at approximately $411,280.02. The trade was a 33.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 278,176 shares of company stock valued at $7,893,316. Corporate insiders own 24.11% of the company’s stock.

Analysts Set New Price Targets

EWTX has been the subject of a number of research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $32.00 target price on shares of Edgewise Therapeutics in a report on Tuesday, September 17th. Truist Financial boosted their target price on shares of Edgewise Therapeutics from $25.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. JPMorgan Chase & Co. raised their price target on shares of Edgewise Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, August 12th. Wedbush upped their price objective on shares of Edgewise Therapeutics from $44.00 to $45.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Finally, Piper Sandler increased their price objective on shares of Edgewise Therapeutics from $48.00 to $51.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $38.40.

Edgewise Therapeutics Trading Down 1.2 %

NASDAQ EWTX opened at $32.87 on Friday. The company has a fifty day simple moving average of $28.93 and a 200 day simple moving average of $22.16. Edgewise Therapeutics, Inc. has a 12-month low of $5.93 and a 12-month high of $38.12. The company has a market cap of $3.11 billion, a P/E ratio of -21.93 and a beta of 0.14.

Edgewise Therapeutics (NASDAQ:EWTX) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.01. Sell-side analysts predict that Edgewise Therapeutics, Inc. will post -1.46 EPS for the current year.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.